Andres Quesada

Clinical evaluation of AI-assisted quantitative marrow fibrosis assessment using Continuous Indexing of Fibrosis (CIF)

Sharon Ruane, Rosalin Cooper, Carlo Pescia, Neha Bhardwaj et autres

Assessment of fibrosis is central to the evaluation of diagnostic bone marrow trephine (BMT) biopsies. However, manual fibrosis grading is subjective and only semi-quantitative. We evaluated the clinical utility of a previously developed AI-based quantitative fibrosis assessment tool, Continuous Indexing of Fibrosis …

gb, it, de, us (code pays fourni par la source)

Table S20 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Patient disposition (Outcomes as of data cutoff: Dec 31, 2024)

Figure S7 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Survival outcomes stratified by KIT status in the 2 treatment groups

Table S5 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Baseline characteristics and outcomes of patients with a pathogenic KIT mutation with VAF>5%

Figure S6 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Survival stratified by status of additional cytogenetic abnormality (ACA)

Figure S13 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Survival outcomes stratified by treatment and End of cycle 3 (EOC3) Optimal PCR Response (OPR) status (landmarked at EOC3)

Figure S18 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Classification and regression tree analysis for End of induction/C1 (EOC1) qPCR value and later risks of relapse (n=157, study set)

Figure S14 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Survival outcomes stratified by End of treatment (EOT) optimal PCR response (OPR) (Landmark=6.6 months from therapy initiation, continuous remission)

Figure S9 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Survival stratified by the presence or absence of DNMT3A-ASXL1-TET2 (DAT) mutation

Table S8 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Cox multivariate model for relapse free survival for the full cohort

Table S15 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Cox multivariate model with backward variable selection for overall survival for FLAG-GO treated patients

Table S18 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Quesada et autres

Cox multivariate model with backward variable selection for relapse free survival in patients who achieved an End of treatment (EOT) Optimal PCR Response (OPR)